Craig Patterson, MD
Critical Care Medicine · Marietta, GANPI 1063624377
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.7% of the total across 154 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 34 manufacturers, the largest accounting for just 21.2% — the pattern of someone who eats at a lot of different presentations.
Across 154 payments — averaging $26.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- United Therapeutics Corporation$871
- Actelion Pharmaceuticals US, Inc.$664
- AstraZeneca$378
- GSK$287
- Bayer$259
- Insmed, Inc.$207
- plus $1K from 28 others
What the payments were for
- Food & beverage$4,099100%
- Education$130%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| United Therapeutics Corporation | 13 | $871 |
| Actelion Pharmaceuticals US, Inc. | 18 | $664 |
| AstraZeneca | 19 | $378 |
| GSK | 16 | $287 |
| Bayer | 9 | $259 |
| Insmed, Inc. | 7 | $207 |
| Vantive US Healthcare LLC | 4 | $174 |
| Merck | 8 | $170 |
| Johnson & Johnson | 12 | $162 |
| Pfizer | 9 | $145 |
| Boston Scientific | 1 | $88 |
| Mallinckrodt Enterprises LLC | 3 | $68 |
| Amgen | 4 | $67 |
| Mylan Specialty L.p. | 3 | $65 |
| Viatris Specialty LLC | 2 | $42 |
| Jazz Pharmaceuticals Inc. | 2 | $41 |
| Regeneron Healthcare Solutions, Inc. | 2 | $40 |
| Boehringer Ingelheim | 2 | $40 |
| Novartis | 2 | $35 |
| Edwards Lifesciences | 1 | $35 |
| ZOLL Medical Corporation | 1 | $33 |
| E.r. Squibb & Sons, L.L.C. | 2 | $31 |
| Sandoz | 2 | $28 |
| Sanofi | 1 | $25 |
| Advanced Respiratory, Inc | 2 | $23 |
| Verona Pharma, Inc. | 1 | $22 |
| Philips North America LLC | 1 | $21 |
| Olympus America Inc. | 1 | $17 |
| Grifols USA, LLC | 1 | $16 |
| Abbott | 1 | $15 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $15 |
| Resmed Corp | 1 | $13 |
| Pulmonx Corporation | 1 | $13 |
| Inogen, Inc. | 1 | $2 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,112 in reported general payments places this provider in the 85th percentile of 265 critical care medicine providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| AdempasRiociguat | 91 | $1,263,186 |
| UptraviSelexipag | 47 | $1,048,728 |
| OpsumitMacitentan | 42 | $527,219 |
| LetairisAmbrisentan | 20 | $258,283 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 230 | $169,042 |
| Dupixent PenDupilumab | 21 | $77,782 |
| AdcircaTadalafil | 12 | $46,342 |
| EliquisApixaban | 45 | $39,027 |
| XareltoRivaroxaban | 21 | $17,914 |
| Breo ElliptaFluticasone/Vilanterol | 18 | $15,332 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 29 | $14,607 |
| Arnuity ElliptaFluticasone Furoate | 19 | $8,360 |
| Ambrisentan | 11 | $6,493 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 24 | $2,929 |
| Wixela InhubFluticasone Propion/Salmeterol | 27 | $2,827 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Actelion Pharmaceuticals US, Inc.Uptravi, Opsumit | $664 | $1,575,94789 claims |
| BayerAdempas | $259 | $1,263,18691 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Arnuity Ellipta | $287 | $207,340296 claims |
| United Therapeutics CorporationAdcirca | $871 | $46,34212 claims |
| PfizerEliquis | $145 | $39,02745 claims |
| Johnson & JohnsonXarelto | $162 | $17,91421 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 265 critical care medicine providers in Georgia.
Other critical care medicine in Marietta
- Asif SaberiMarietta$5K
- Alexander GluzmanMarietta$4K
- Sarah BlackstockMarietta$4K
- Nikulkumar ChaudhariMarietta$2K
- Salman FidahusseinLagrange$852K
- Bruce FriedmanAugusta$629K
- Gregory MauldinSnellville$221K
- Ramzy RimawiAtlanta$72K
- Rafael Alba YunenBrunswick$58K
- April McDonaldGainesville$41K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.